SECTION 16 METABOLIC BONE DISEASE
whose GFR is reduced due to intrinsic parenchymal damage as opposed to age-related reductions in GFR without another specific intrinsic renal diagnosis.
At each level of CKD there may exist a specific form of renal osteodystrophy. The earliest form of renal bone disease (secondary hyperparathyroidism) may be defined by quantitative histomorphometry and/or biochemical profiling (elevated 1-84 intact parathyroid hormone [PTH] ) as early as stage 3 CKD (GFR 30 to 60 mL/min). Even though there is an exponential relationship between the declining level of GFR and the height of the endogenous PTH, elevated PTH levels (secondary hyperparathyroidism) may also be seen in patients with various forms of osteoporosis due to many other possible causes that may not be related to reduced GFR (e.g., low 25-hydroxyvitamin D levels, calcium malabsorption, hypercalciuria). Only after correcting other reversible factors that may also lead to secondary hyperparathyroidism while the PTH remains elevated in association with reduced GFR can the secondary hyperparathyroidism be attributed to the reduction in renal function.
The KDOQI guidelines (both opinion-and evidence-based) provide suggestions concerning the management of secondary hyperparathyroidism when due to intrinsic renal damage. 3 In addition, there are published suggestions for the management of patients with postmenopausal, male, and glucocorticoid-induced osteoporosis who have secondary hyperparathyroidism not related to reduction in renal function. [5] [6] [7] [8] [9] [10] [11] The other forms of renal bone disease (osteomalacia, mixed renal osteodystrophy, adynamic renal bone disease, and aluminum bone disease) are rare until stage 5 CKD (end-stage renal disease with GFR less than 15 mL/min or on dialysis). The classification of renal bone disease is most objectively defined by double tetracycline-labeled quantitative histomorphometry, and quantitative histomorphometric criteria for defining the specific form of renal bone disease (standardized nomenclature) have been published. 12 Hence, here the means by which renal osteodystrophy is first defined is divided into quantitative bone histomorphometry, then biochemical profiling, and, finally, clinically. In addition, the challenge of defining osteoporosis, a common metabolic bone disease in the CKD population, will be discussed. Finally, the therapeutic options that are available to treat specific forms of renal bone disease and osteoporosis associated with CKD will be presented.
QUANTITATIVE BONE HISTOMORPHOMETRY
Double tetracycline-labeled quantitative bone histomorphometry is the gold standard for defining the specific forms of renal osteodystrophy. 1, 2, 12, 13 Recently, several comprehensive atlases of renal bone disease have been published that describe in depth the normal bone remodeling process as measured by histomorphometry and then show examples of bone biopsies with detailed descriptive analysis of each form of renal osteodystrophy. 1, 2 In addition, these atlases deal with histomorphometric data in postrenal transplantation bone disease and also provide histologic and clinical guidance for the diagnosis of osteoporosis in patients with CKD. The following is a brief description of the forms of renal osteodystrophy.
Although, in general, the classification is divided into high or normal bone turnover versus low bone turnover forms by biochemical markers of bone turnover, [14] [15] [16] the specific diagnosis is based on specific quantitative double tetracycline-labeled bone histology. 1, 2, 12, 13 The KDOQI was the first attempt to provide broad guidelines for management of calcium, phosphorus, PTH, and bone abnormalities accompanying CKD, 3 
INTRODUCTION
Renal osteodystrophy constitutes a heterogeneous group of metabolic bone disorders that accompany declining glomerular filtration rate (GFR) (Box 201.1). 1,2 Whereas one of these forms of renal bone disease may be present in patients at different stages of chronic kidney disease (CKD), patients may also move from one form to another, either as a process of the natural biology of renal bone disease or as a result of the treatments that are used to manage a specific form of renal bone disease.
The National Kidney Foundation's (NKF) Disease Outcome Quality Initiative (KDOQI) has classified the degrees of CKD according to GFR in patients with known intrinsic renal disease (Table 201.1) . 3 In addition, aging is also associated with a reduction in GFR even without any known intrinsic renal disease. The third U.S. National Health and Nutrition Examination Survey (NHANES III) has reported that 25% of otherwise healthy adults have GFR levels less than 25 mL/min (Table  201. 2). 4 It is not known whether bone metabolism differs in patients understanding of the link between bone turnover, mineralization, and volume to the systemic vascular calcification that leads to the most prevalent cause of death in CKD patients, termed chronic kidney disease/mineral and bone disorder (CKD/MBD). 17 Bone biopsy should be considered in the following special clinical circumstances in patients with CKD. 1, 2, [6] [7] [8] 13, [18] [19] [20] [21] [22] [23] • In patients with fragility fractures, because patients with all forms of renal osteodystrophy may fracture and making the correct diagnosis is paramount to choosing the correct treatment. As will be discussed in the section on biochemical markers of bone turnover (BTM), there is a great deal of overlap in biochemical markers that limit their specificity in discriminating between the heterogeneous forms of renal osteodystrophy. [14] [15] [16] Furthermore, the diagnosis of osteoporosis, a very prevalent metabolic bone disease in patients with CKD, cannot be made in patients with stage 4-5/5D CKD by BMD (WHO) criteria established for postmenopausal osteoporosis, nor by the presence of fragility fractures. [5] [6] [7] [8] 18 • In patients with unexplained elevation of bone-specific alkaline phosphatase to exclude osteomalacia • In patients with severe secondary (e.g., tertiary) hyperparathyroidism before parathyroidectomy to be certain that there is no aluminum in bone. Parathyroidectomy before aluminum is removed will mitigate the ability of deferoxamine (DFO) to chelate and remove bone aluminum.
• Before initiating DFO chelation to remove bone aluminum in patients with suspected aluminum renal bone disease to be absolutely certain that aluminum is present in bone. Serum aluminum levels may not always reflect the presence of bone aluminum.
• In patients with suspected adynamic renal bone disease based on biochemical profiles (hypercalcemia, low bone-specific alkaline phosphatase [BSAP] levels, lower intact PTH levels [100 to 500 pg/mL] or a ratio of 1-84/7-84 [scantibodies] PTH < 1.0).
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• Before treating stage 5/5D (dialysis) CKD patients with osteoporosis-specific pharmacologic agents for suspected osteoporosis because both osteomalacia and adynamic renal bone disease are diseases in which bisphosphonates and other agents that reduce bone turnover are not recommended.
Transiliac bone biopsies are safe procedures that, in experienced hands, are associated with a very low morbidity and minimal postoperative pain. By utilizing minimal-awareness conscious sedation and renal bone disease may be due, for example, to oversuppression of PTH by a vitamin D analog or cinacalcet (Sensipar), it may be simpler to discontinue or reduce the dosage of the vitamin D analog or cinacalcet, allowing the endogenous PTH to increase. However, clinical questions still remain unanswered if these modifications are made to allow the PTH level to rise. For example, does the increase in PTH translate into an improvement in bone turnover or fracture risk reduction in patients with iatrogenically induced adynamic renal bone disease? Bone histomorphometry, measuring bone formation rates and mineral apposition rates both before and after modification of factors that might be associated with adynamic bone disease, might be the most objective means by which to monitor the influence of any modification designed to alter rates of bone turnover. 25 Patients with renal osteodystrophy may move from one form of renal bone disease to another, and accompanying these transitions are distinct biochemical as well as histomorphometric changes that reflect the transition. [14] [15] [16] [17] For example, as CKD progresses through stages 3 to 5, there is progressive development of secondary hyperparathyroidism that often resolves after renal transplantation and may then return again if there is a transplant rejection and a return to dialysis. 16, 17, 20 Management decisions surrounding renal transplantation have been the topic of recently published texts. 15, 26 Using biochemical tests to manage individual derangements in chemical values that develop during the progression of CKD is a common means by which clinical nephrologists attempt to prevent the consequences of the development of hyperphosphatemia, metabolic acidosis, hyperparathyroidism, osteomalacia, and aluminum bone disease. The reader is referred to previously published details on the management of the metabolic derangements that are seen in the progressive stages of CKD. 3, 16, 17, 20 HYPERPHOSPHATEMIA Hyperphosphatemia occurs as GFR declines due to the restricted capacity of the renal tubule to increase absolute urinary phosphorus excretion. The tubular reabsorption of phosphorus (TRP) decreases as the filtered phosphorus load decreases to maintain the absolute urine phosphorus excretion and prevent hyperphosphatemia. The mediators of the decrease in the TRP are the rising PTH and osteocyte-derived fibroblast growth factor-23 (FGF23). 27, 28 However, the TRP can only decline to a limited degree even though the serum PTH and FGF23 levels continue to rise.
In the original description of the "trade-off hypothesis," one of the causes of the progressive rise in endogenous PTH as GFR declined is the retention of phosphorus and the subsequent adaptation to maintain a normal serum phosphorus (to keep the calcium × phosphorus product normal so as to mitigate soft tissue calcification). The trade-off is the development of progressive secondary hyperparathyroidism. 23 Hence, in an ideal CKD management scenario, one restricts dietary phosphorus intake at certain levels of GFR to prevent the subsequent development of secondary hyperparathyroidism (which is now known to be related to multifactorial cascades: hypocalcemia, reduced renal production of 1,25-dihydroxyvitamin D, and a direct effect of elevated appropriate cardiopulmonary monitoring, using frequently sharpened trocars, and with careful postoperative care, the proportion of patients having any postoperative pain is very small.
BIOCHEMICAL PROFILING
The laboratory tests that should routinely be measured in renal disease, especially from stage 3 CKD onward, include serum calcium, phosphorus, PTH, BSAP, creatinine, chloride, carbon dioxide, and 25-hydroxyvitamin and 1,25-dihydroxyvitamin D levels. 3, [14] [15] [16] [17] Many of these tests are measured annually in patients with stage 1-3 CKD, quarterly in patients with stage 4 CKD, and often monthly in patients with stage 5/5D CKD. The reason for measuring these biochemical profiles is to detect when the serum phosphorus concentration begins to rise or when metabolic acidosis or secondary hyperparathyroidism begins to appear. Because secondary hyperparathyroidism may be due to deficiency of either vitamin D metabolites, correlating the PTH levels to vitamin D levels allows discrimination between rising PTH due to vitamin D deficiency and PTH elevation that might rise due to hyperphosphatemia and/or reduced GFR. [20] [21] [22] [23] Biochemical tests are done for two distinctly separate reasons: (1) to try to predict the histomorphometry in patients with CKD and (2) to make clinical management decisions to prevent the development of hyperphosphatemia, metabolic acidosis, and hyperparathyroidism.
The utilization of biochemical profiling for characterizing the type of renal bone disease as defined by histomorphometry has value in groups of patients but loses both sensitivity and specificity in individual patient management. 14 Previous publications defined these biochemical-histologic relationships in much greater detail. 3, 17 In general, patients with intact PTH (1-84) levels six times the upper limit of normal have a high probability of having osteitis fibrosa cystica. In turn, patients who have low levels of PTH and BSAP have a higher probability of having renal-related very low bone turnover or even adynamic or aluminum bone disease or low bone turnover osteoporosis. 3, 16, 20 Hence, while the biochemical profiles are helpful in groups of patients, there is enough overlap such that biochemical profiles may not accurately reflect the bone histology in individual patients to make bone biopsy a necessity to achieve the correct diagnosis before specific management decisions are made. For example, as stated, although PTH levels are ordinarily lower (<150 pg/mL) in patients with adynamic renal bone disease, 3, 17 published data suggest that as many as 50% of patients with biopsy-proven adynamic renal bone disease have intact PTH levels greater than 500 pg/mL. 19 These situations may be associated with higher levels of a catabolic parathyroid hormone (7-84 PTH) and a ratio of 1-84 to 7-84 of less than 1.0. Although it is biologically reasonable to assume that a patient having a 1-84/7-84 ratio of less than 1.0 and a low BSAP has a higher probability of having adynamic renal bone disease, the data validating this are lacking, making biopsy a necessity before major management decisions are made.
There are non-modifiable as well as modifiable causes of adynamic bone disease (see Box 201.1). 24 If the clinician suspects that adynamic disease (ESRD) patients with severe secondary hyperparathyroidism. Although current guidelines suggest reducing PTH levels to less than 250 pg/mL in ESRD patients, there is a concern about oversuppression of bone turnover that may lead to the development of adynamic bone disease if PTH levels are reduced too low. 24, 25 There is currently no universal consensus about the safe level of reduction of PTH. The KDIGO suggests watching the trend of PTH rather than making a clinical decision based on a single determination.
Surgical parathyroidectomy is indicated in patients with stage 5 CKD who have severe hyperparathyroidism not manageable by vitamin D analogs or cinacalcet. Parathyroidectomy (PTX) is suggested in ESRD patients with persistent elevations of PTH levels greater than 800 pg/mL associated with persistent hypercalcemia, bone fractures, soft tissue calcification, or hyperphosphatemia.
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OSTEOMALACIA
Osteomalacia, another form of low bone turnover, may also be seen in CKD and has a variety of causes (Fig. 201.1) . Whereas aluminum accumulation on the surfaces of osteoid is one of the reversible causes of osteomalacia, this disease may also be seen in the absence of aluminum accumulation and be related to either deficiency or insufficiency of 25-hydroxyvitamin D levels, low 1,25-dihydroxyvitamin D levels, chronic hypophosphatemia, or chronic metabolic acidosis.
There are specific quantitative histomorphometric criteria for the classification of osteomalacia.
1,2,13 Although low bone turnover may be seen in a variety of disease states, including osteoporosis, osteomalacia per se has very specific diagnostic criteria.
Because all forms of osteomalacia have a distinct treatable etiology, the correct diagnosis is essential for effective therapy. In clinical practice, osteomalacia is suspected when there is an elevation of the BSAP. Nevertheless, in renal osteodystrophy the BSAP may also be elevated in hyperparathyroid bone disease. The BSAP may also be elevated in some patients with postmenopausal or age-related osteoporosis. Patients with osteomalacia and osteoporosis may develop fragility fractures. As will be discussed, bisphosphonates are contraindicated in patients with osteomalacia. Thus, it becomes especially important to differentiate osteoporosis from osteomalacia, especially in an ESRD patient who has fragility fractures. Here, too, double tetracyclinelabeled bone biopsy is the single most objective means to make the differential diagnosis.
Osteomalacia is treatable and if due to very low and sustained levels of 25-hydroxyvitamin D, increasing the 25-hydroxyvitamin D levels to more than 30 ng/mL will be accompanied by a reduction and ultimately a normalization of the BSAP. To increase vitamin D levels to normal in the elderly population, it often requires 50,000 units of vitamin D 2 per week for a period of time to be effective. Monitoring the BSAP, 25-hydroxyvitamin D, PTH, and serum calcium levels must be done periodically, titrating the vitamin D replacement accordingly.
serum phosphorus level and FGF23 to reduce PTH production). Restriction of dietary phosphorus is difficult because phosphorus is ubiquitous in the food chain. In addition, serum phosphorus concentrations may vary because of the cellular shifts in phosphorus that occur after a glucose load or change in acid-base status. Thus, mild and intermittent hyperphosphatemia may not be recognizable in stage 1 to 3 CKD. Persistent elevation of serum phosphorus may only be seen in stage 4 to 5 CKD; yet, secondary hyperparathyroidism often precedes this development. Hence, in both the KDOQI and KDIGO guidelines, the recommendation is to restrict dietary phosphorus and, if this is ineffective, to use one of the vitamin D analogs to suppress PTH values in stage 3 and 4 CKD when PTH levels rise to more than 70 pg/mL (stage 3 CKD) or 110 pg/mL (stage 4 CKD) on more than two consecutive measurements. The purpose is to mitigate the effects of chronic elevation of PTH on skeletal health.
Even though the KDOQI and KDIGO guidelines suggest early intervention with vitamin D analogs to suppress PTH values, a fundamental question is raised: Is there enough evidence that mild elevations of PTH induce sufficient negative skeletal consequences to justify interventions to reduce the PTH levels? The evidence supporting this hypothesis is weak, although there are preliminary data suggesting a greater skeletal fragility even in early CKD. 29, 30 The acknowledged evidence that specific vitamin D analogs suppress PTH levels drives the opinion that early reduction of PTH is beneficial. Limited data from paired bone biopsies suggest improvement in hyperparathyroid histologic features by early suppression of PTH, but there are no data on the effect of such early intervention on fragility fracture risk or on changes in BMD. In addition, use of the vitamin D analogs (calcitriol 0.25 mg/day; α-calcidiol 0.25 mg/day; or doxercalciferol 2.5 mg 3 times a week), although capable of lowering serum PTH levels also requires close safety monitoring for potential harmful effects of these potent agents: the induction of hypercalcemia or hyperphosphatemia or lowering GFR.
Although there is greater consensus in the nephrology community with regard to suppressing PTH in patients with CKD stage 5/5D, with the use of vitamin D analogs or cinacalcet, especially in patients with clear-cut clinical abnormalities related to their excessive PTH (hypercalcemia, radiographic evidence of osteitis fibrosa cystica, elevated BSAP levels, soft tissue calcification, fragility fractures, or decline in BMD), there is less consensus about suppressing PTH in patients with stage 3 or 4 CKD. The use of the pharmacologic modalities designed to suppress PTH levels in patients with CKD is probably best directed by either nephrologists or specialists with a keen interest in metabolic bone diseases. In patients with CKD, before or during the use of vitamin D analogs it is also very important to maintain the serum phosphorus concentration in a normal range to mitigate the potential for soft tissue calcification. As discussed later, one potential advantage of using cinacalcet as opposed to vitamin D analogs to suppress PTH levels are the data that cinacalcet does not increase serum phosphorus or calcium in CKD patients.
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HYPERPARATHYROIDISM
As GFR declines in progressive CKD, PTH levels rise. There is increased PTH production as GFR declines due to hypocalcemia, hyperphosphatemia, and/or reduced renal production of 1,25-dihydroxyvtamin D. This GFR/PTH relationship becomes exponential as GFR falls to levels under 30 mL/min. As previously discussed, control of the serum phosphorus and calcium concentrations as well as vitamin D analogs is one approach to preventing secondary hyperparathyroidism. In stage 5 CKD, PTH levels may often be very elevated and the clinical consequences from secondary hyperparathyroidism more severe as well. The highest PTH levels seen in human biology are in stage 5 CKD and may lead to severe hypercalcemia, soft tissue calcifications, high bone turnover with associated elevated BSAP, severe osteitis fibrosa cystica, loss of BMD, and fragility fractures.
Cinacalcet (initially at a dose of 30 mg/day with the dosage titrated to achieve an intact PTH level < 250 pg/mL) normalized serum calcium and BSAP levels and, in contrast to the hyperphosphatemia that may be seen with the use of vitamin D analogs, lowered the serum phosphorus concentrations as well. Careful monitoring of PTH values is important if inhibitors of PTH production are used in end-stage renal PTH level has been more than 500 pg/mL in biopsy-proven adynamic bone disease. 19 Thus, bone histomorphometry becomes a necessity in these patients.
In patients with severe CKD who are experiencing fractures and have low BMD and clinical reasons suggesting osteoporosis, biopsy is often a necessity before initiating bisphosphonates to reduce fracture risk. Bisphosphonates are relatively contraindicated in adynamic bone disease. Use of an agent that reduces bone turnover in patients who already have preexisting low bone turnover could possibly be detrimental. 34, 35 The hypothesis remains untested, although plausible, that bisphosphonates could make adynamic bone disease worse and increase bone fragility. Oversuppression of bone turnover leading to bone fragility that might be induced by bisphosphonates has been suggested by anecdotal data but remains an unproven hypothesis. [34] [35] [36] [37] It is also plausible that bisphosphonates mitigate vascular calcification. [38] [39] [40] However, in those ESRD patients in whom adynamic bone disease is defined by quantitative bone histomorphometry (see Fig. 201. 2), 1 bisphosphonates should not be given to augment bone strength.
A biochemical profile that has been suggested to provide a possible enhanced sensitivity to the non-invasive diagnosis of adynamic bone disease is the ratio of 1-84/7-84 PTH (scantibodies). 19 The PTH sequence of 7-84 is catabolic to bone turnover and may be secreted from the parathyroid cell through its own genomic pathway. There is a good correlation between the quantitative bone histomorphometry findings of ESRD with the 1-84/7-84 ratio, if the ratio is less than 1.0. It is hypothesized that those patients with adynamic bone disease who have high levels of PTH may have adynamic bone disease because of higher levels of 7-84 PTH. If these preliminary observations are substantiated by future data, it may explain why some patients with adynamic renal bone disease have elevated (rather than suppressed) 1-84 PTH levels. There are also published data suggesting that the ratio of 1-84/7-84 PTH may not be as sensitive for diagnosing adynamic bone disease as earlier data suggest. 17, 41, 42 A bone biopsy is therefore still necessary to be certain.
METABOLIC ACIDOSIS
Patients with CKD develop metabolic acidosis, most commonly due to the accumulation or reduced excretion of organic anions. This is most often seen when the GFR reaches less than 30 mL/min. A non-anion gap metabolic acidosis (renal tubular acidosis [RTA]) may be seen at any level of GFR and in patients without any reduction in renal function. Either proximal (rare) or distal (common) RTA can lead to either osteomalacia or osteoporosis. The reader is referred to more in-depth literature on this subject. 43, 44 In patients with CKD, the serum CO 2 level should be measured and, if necessary, maintained at more than 22 mmol/L with alkali salts. However, it is important not to use citrate as the alkali salt because this enhances the intestinal absorption of aluminum. In clinical practice it is important to confirm that the low CO 2 is due to a metabolic acidosis and not a respiratory alkalosis by arterial blood gas analysis.
OSTEOPOROSIS
Although osteoporosis is not listed in the literature as a form of renal osteodystrophy, the consideration that some form of osteoporosis rather than a renal-related metabolic bone disease is causing fractures will take on more significance in clinical practice. There are many reasons why CKD patients may develop osteoporosis. [6] [7] [8] 11 As patients with CKD live longer, more will also have an increased risk for the development of osteoporosis.
How does one make the diagnosis of osteoporosis in patients with CKD? All forms of renal bone disease may be associated with fragility fractures or low BMD. Therefore, neither fractures nor the WHO criteria (BMD T-score of −2.5 or below) can be used with certainty to make a diagnosis of osteoporosis in patients with stage 4-5/5D CKD. The recent KDIGO working group does support the use of the WHO criteria for the diagnosis of osteoporosis in stage 1 to 3 CKD. 17 Because biochemical profiling cannot clearly discriminate among the various forms of renal osteodystrophy with certainty, it also cannot be used to make a diagnosis of osteoporosis. Hence, it becomes a necessity to differentiate between the renal osteodystrophies and osteoporosis by Although the prevalence of aluminum bone disease has decreased with the less frequent use of aluminum-containing phosphate binders, it is still surprisingly common. The KDOQI guidelines suggest maintaining the dialysate fluid aluminum concentration at less than 10 mg/L. In addition, KDOQI guidelines recommend treating symptomatic ESRD patients with basal serum aluminum levels greater than 60 mg/L or observing a rise of serum aluminum of 50 mg/L or more after a DFO challenge test. The treatment for aluminum bone disease or aluminum-induced dementia is long term (4 to 6 months) at DFO doses of 5 mg/kg intravenously over 1 hour before hemodialysis, one to two times per week. DFO has risks: in patients with high basal (>200 mg/L) serum aluminum levels, DFO-induced redistribution of aluminum from bone may induce neurotoxicity. In such cases it is suggested that intensive (6 days/week) high-flux hemodialysis be performed first to achieve predialysis serum aluminum levels less than 200 mg/mL before DFO initiation. In addition, the risk of certain fungal infections, including rapidly progressive mucormycosis, may exist, especially in diabetics. Hence, one should be as certain as possible that aluminum bone disease is present before initiating the potentially toxic DFO therapy. Here again, bone biopsy with aluminum staining is diagnostic. In addition, a repeat bone biopsy after the completion of the DFO treatment course is the most sensitive way to be certain that the aluminum has been removed. It is not uncommon to have normal basal and post-DFO challenge serum aluminum levels and yet still have abundant aluminum covering osteoid surfaces.
ADYNAMIC RENAL BONE DISEASE
Adynamic renal bone disease is an increasingly prevalent form of renal osteodystrophy that may be associated with fragility fractures and low BMD and variable biochemical profiles ( Fig. 201.2) . 13, 16, 17, 19, 25 Adynamic bone disease was initially seen predominantly in diabetic patients with ESRD on peritoneal dialysis, even in patients who had not received interventions to reduce PTH levels. However, the prevalence of this disease seems to be increasing.
Although there are forms of adynamic bone disease that have no apparent cause, there may be modifiable as well as non-modifiable forms. 24 It is probable that oversuppression of PTH, whether by vitamin D analogs, cinacalcet, or parathyroidectomy, may lead to some forms of adynamic bone disease. In theory, those forms of adynamic bone disease that are induced by pharmacologic suppression of PTH may become reversible once the responsible agent is removed. However, there are situations in which adynamic bone disease is seen without an identifiable etiology and these recalcitrant forms are very problematic because many of these patients develop severe fragility fractures. 32, 33 In addition, as previously stated, biochemical profiling may not be sensitive or specific enough to make a diagnosis of adynamic bone disease in the individual patient. In fact, in some reports the intact Recent post-hoc data from the teriparatide fracture prevention trial suggest that teriparatide is also safe and effective down to GFR levels of 30 mL/min. 50 Efficacy was measured by improvements in BMD and osteoblast activity markers (pro-peptide type I collagen). If there is a reversible cause of an elevated PTH in a patient with stage 3 CKD, these abnormalities should be corrected first, to see the effect on the serum intact PTH before initiating teriparatide. Even if the patient's PTH does not normalize and seems to be elevated due to CKD alone, there may be a very different effect on bone strength by administering PTH in "pulses" even in bone exposed to chronic elevations of PTH. To the extent that teriparatide is safe down to GFR levels of 30 mL/ min, it should be considered as a possible therapy in very specific circumstances.
CONCLUSION
Renal osteodystrophy is a heterogeneous group of metabolic bone diseases associated with declining GFR values. There are many causes and clinical presentations that often cannot be distinguished from one another without quantitative bone histomorphometry, especially in stage 4-5/5D CKD. Once the diagnosis is clear, all forms of renal osteodystrophy have many reversible causes; some remain "idiopathic." Newer therapies with vitamin D analogs or cinacalcet can mitigate one form of renal osteodystrophy: secondary hyperparathyroidism. Osteoporosis also occurs in CKD patients and has a clinical presentation not easily indistinguishable from "renal bone disease," fractures, and low bone mass. Nevertheless, osteoporosis does occur in CKD and may be amenable to interventions designed to reduce fracture risk in patients with osteoporosis with normal renal function. The recent KDIGO report has expanded the relationships between bone mineralization, turnover, and volume to link the bone derangements in CKD to the systemic vascular calcification (CKD/MBD). Physicians need guidance on how to diagnose and treat osteoporosis in their CKD patients, especially stage 4-5/5D CKD for which evidence-based data are nearly non-existent. quantitative bone histomorphometry. This is especially true if the physician believes that the patient has osteoporosis and contemplates the use of osteoporosis-specific pharmacologic agents designed to improve bone strength and reduce the risk of fracture. 45 Although hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), and calcitonin can reduce fracture risk in postmenopausal women, older men, or patients with glucocorticoid-induced osteoporosis, they may have limitations in patients with CKD. HRT and SERMs increase the risk for venous thromboses, and there is no evidence that calcitonin reduces the risk of non-vertebral or hip fractures. These latter forms of fragility fractures are common in patients with CKD. Thus, physicians caring for patients with CKD who also have fragility fractures often ask about the use of bisphosphonates or even teriparatide (rh1-34 PTH) for patients with CKD.
The FDA suggests not using bisphosphonates in patients with creatinine clearances less than 30 to 35 mL/min. This warning is not a contraindication to bisphosphonate use in patients with stage 4 to 5 CKD but is mostly based on the lack of evidence of safety in patients with more severe CKD and on data from animal studies indicating that much higher oral doses of bisphosphonates may induce a renal lesion and reduced GFR.
Recent post-hoc pooled analyses obtained from the risedronate clinical trial dataset indicate that daily doses of risedronate (5 mg/day) are safe (do not alter serum creatinine concentrations) and effective (reduction in incident vertebral fracture risk) in patients with GFR levels between 15 and 30 mL/min. 46 In addition, a post-hoc analysis from the alendronate postmenopausal registration trials also demonstrated that the daily formulations of alendronate are also safe and effective to reduce all clinical fractures in women with an estimated GFR (eGFR) as low as 15 mL/min. 47 Similar post-hoc data has also been reported from the raloxifene postmenopausal registration trial. 48 These post-hoc analyses need to be confirmed by prospective studies; however, the data do suggest that FDA-approved doses of oral bisphosphonates are safe and effective even in patients with stage 4 CKD. 49 These data may not apply to patients with stage 5/5D CKD, those with ESRD, or the postrenal transplant population.
The clinical question often arises about what dose of oral bisphosphonates should be considered in patients with stage 5 CKD or on dialysis. Here we have no evidence and only opinion exists. Because of the known pharmacokinetics of oral bisphosphonates, using 50% of the dose prescribed for patients with normal GFR in stage 4 CKD seems reasonable, recognizing that bone affinities, bone retention time, and bone accumulation may be very different in patients with GFR values less than 15 mL/min or even among the various oral bisphosphonates.
What about the use of teriparatide in patients with CKD? There should be no reason why teriparatide should not be effective to reduce
